Neoadjuvant chemotherapy followed by hyperthermic intraperitoneal chemotherapy for patients with colorectal peritoneal metastasis: a retrospective study of its safety and efficacy

Abstract Background Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are effective routine treatments for colorectal peritoneal metastasis (PM). However, the safety efficacy of neoadjuvant (NAC) before CRS+HIPEC poorly understood. Therefore, this study aimed to assess perioperative long-term NAC prior patients with synchronous PM. Methods Patients PM who received were systematically reviewed at China National Cancer Center Huanxing Hospital from June 2017 2019. The clinicopathologic characteristics, parameters, survival rates underwent (NAC group) without (non-NAC compared. Results enrolled 52 patients, 20 in group 32 non-NAC group. In group, proportion a carcinomatosis index (PCI) score < 12 was significantly higher than that (80.0% vs 50.0%, P = 0.031), more achieved complete cytoreduction 46.9%, 0.018). two groups had comparable grade III/IV complications similar reoperation mortality ( > 0.05). lower platelet counts (151.9 197.7 × 10 9 /L, 0.036) neutrophil (4.7 7.2 0.030) on postoperative day 1. More survived 2 years (67.4% 32.2%, respectively, 0.044). completeness (HR, 2.99; 95% CI, 1.14–7.84; 0.026), rather NAC, independently associated overall (OS) multivariate analysis after controlling confounding factors. Conclusion administration can be regarded as safe feasible comparably low acceptable morbidity rates. Nevertheless, large-sample randomized controlled studies needed confirm whether confers benefit patients.